IP Library › Granted Patent US 11,357,826
Granted Patent B2
US 11,357,826 · App. 16/547,158 · Granted Jun 14, 2022

IL-10 EGFR antibody fusion protein and uses thereof

Inventors: Ting Xu (Jiangsu, CN); Yan Luan (Jiangsu, CN); Jianjian Peng (Jiangsu, CN); Shuli Ma (Jiangsu, CN); Meng Zhao (Jiangsu, CN); Xiaoxiao Wang (Jiangsu, CN); Hui Ma (Jiangsu, CN); Shilong Fu (Jiangsu, CN); Xiaolong Pan (Jiangsu, CN); Shanshan Ning (Jiangsu, CN)
Assignee: DINGFU BIOTARGET CO., LTD.
A61K38/19C07K14/5428C07K14/56C07K14/565C07K16/2863C12N15/62C12N15/63A61K38/00C07K19/00C07K2317/92C07K2319/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,826
App. No.
16/547,158
Granted
Jun 14, 2022
Kind
B2
Abstract

The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

Claims (9)

1. A proteinaceous complex formed by:

a light chain and a heavy chain of an antibody specific for EGFR;

wherein the variable domain of said light chain and the variable domain of said heavy chain respectively comprise SEQ ID NOs: 37 and 38; and

(ii) a fusion polypeptide comprising, from N-terminus to C-terminus, a cytokine fused to an antibody Fc region via a linker, wherein the cytokine is interleukin 10;

wherein the amino acid sequence of the fusion polypeptide comprises SEQ ID NO: 51; and

wherein said antibody Fc region of the fusion polypeptide of (ii) complexes with the antibody heavy chain of (i) to form a dimer.

2. A pharmaceutical composition comprising the proteinaceous complex of claim 1 and a pharmaceutically acceptable carrier.

3. A method for inhibiting growth of a tumor or a tumor cell, comprising contacting said tumor or tumor cell with an effective amount of the proteinaceous complex of claim 1 .

4. A method for treating cancer in a patient, comprising administering a therapeutically effective amount of the proteinaceous complex of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: DINGFU BIOTARGET, CO., LTD.
To: SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD.
Reel/Frame 068654/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2021
From: XU, TING; LUAN, YAN; PENG, JIANJIAN; MA, SHULI; ZHAO, MENG; WANG, XIAOXIAO; MA, HUI; FU, SHILONG; PAN, XIALONG; NING, SHANSHAN
To: DINGFU BIOTARGET CO., LTD.
Reel/Frame 057353/0479 →
Continuity (2)
Division 15528909
Related Publication 20200069773A1 · Mar 5, 2020
Cited By (4)
US 12,280,120 US 12,365,713 US 12,577,325 US 12,662,520